– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option – – Esperion Aims to Set New Industry Standard by ...

Esperion Therapeutics (NASDAQ:ESPR) shares gained 7% premarket on Monday after the company touted clinical benefits of NEXLETOL (bempedoic acid) tablets in diverse populations, including women, ...

– Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated Approval in 1H 2024 – ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- ...

ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, ...